iQure Pharma develops therapeutics targeting neurodegenerative diseases, utilizing preclinical compounds iQ-007 and iQ-008 that have shown promising results in zebrafish models. The company aims to address the lack of effective treatments for these conditions by advancing iQ-007 into Phase 1 clinical trials in early 2025.
Funding
$8.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases lack effective treatments, leaving a significant unmet need for therapies that can slow or reverse disease progression. Current treatment options often only manage symptoms without addressing the underlying causes of neuronal damage and loss. This results in a decline in cognitive and motor function, impacting the quality of life for patients and their families.
Solution
iQure Pharma is developing novel therapeutics, iQ-007 and iQ-008, designed to target the underlying mechanisms of neurodegenerative diseases. These preclinical compounds have demonstrated promising results in zebrafish models, suggesting potential efficacy in treating a range of neurodegenerative conditions. The company is focused on advancing iQ-007 into Phase 1 clinical trials, representing a critical step towards evaluating its safety and efficacy in humans. iQure Pharma's approach aims to provide disease-modifying treatments that can improve patient outcomes and address the limitations of existing therapies.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases, their families, and healthcare providers specializing in neurology and neurodegenerative disorders.
Features
- iQ-007: A novel therapeutic compound in preclinical development, preparing for Phase 1 clinical trials in early 2025.
- iQ-008: A second therapeutic compound in preclinical development.
- Demonstrated positive results in zebrafish models for neurodegenerative diseases.